Marshall Urist's most recent trade in Royalty Pharma plc - Ordinary Shares - Class A was a trade of 9,099 Class A Ordinary Shares done at an average price of $55.9 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 55.88 per share. | 01 Jul 2026 | 9,099 | 0 | - | 55.9 | 508,454 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 55.18 per share. | 24 Jun 2026 | 9,098 | 9,099 | - | 55.2 | 502,067 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 52.75 per share. | 20 May 2026 | 13,684 | 18,197 | - | 52.8 | 721,838 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 53.06 per share. | 14 May 2026 | 13,684 | 31,881 | - | 53.1 | 726,137 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2026 | 18,197 | 45,565 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 19,970 | 27,368 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 41.09 per share. | 30 Jan 2026 | 20,000 | 0 | - | 41.1 | 821,810 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 40.26 per share. | 23 Jan 2026 | 20,000 | 20,000 | - | 40.3 | 805,110 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.52 per share. | 16 Jan 2026 | 20,000 | 40,000 | - | 39.5 | 790,346 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 40.78 per share. | 09 Jan 2026 | 20,000 | 60,000 | - | 40.8 | 815,634 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 38.48 per share. | 02 Jan 2026 | 20,000 | 80,000 | - | 38.5 | 769,650 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.32 per share. | 26 Dec 2025 | 20,000 | 100,000 | - | 39.3 | 786,380 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 38.38 per share. | 19 Dec 2025 | 20,000 | 120,000 | - | 38.4 | 767,582 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 16 Dec 2025 | 20,000 | 140,000 | - | 38.3 | 766,420 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.15 per share. | 05 Dec 2025 | 23,334 | 160,000 | - | 39.2 | 913,591 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.15 per share. | 05 Dec 2025 | 18,242 | 7,398 | - | 39.2 | 714,224 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.93 per share. | 01 Dec 2025 | 23,333 | 183,334 | - | 39.9 | 931,633 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.90 per share. | 01 Dec 2025 | 18,242 | 25,640 | - | 39.9 | 727,856 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 05 Nov 2025 | 160,000 | 206,667 | - | 0 | Class A Ordinary Shares | ||
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 05 Nov 2025 | 16,000 | 247,412 | - | - | LP interests in RPI US Partners 2019, LP | ||
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2025 | 4,626 | 43,882 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2025 | 3,000 | 263,412 | - | - | LP interests in RPI US Partners 2019, LP | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2025 | 2,772 | 39,256 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 1,356,528 | 1,356,528 | - | - | Class E Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 36,484 | 83,151 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Aug 2024 | 2,182 | 126,412 | - | - | LP interests in RPI US Partners 2019, LP | |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 37.30 per share. | 22 Feb 2023 | 23,333 | 46,667 | - | 37.3 | 870,239 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 17 Feb 2023 | 70,000 | 70,000 | - | 0 | Class A Ordinary Shares | ||
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 17 Feb 2023 | 7,000 | 128,594 | - | - | LP interests in RPI US Partners 2019, LP | ||
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 43.20 per share. | 25 Jul 2022 | 19,734 | 0 | - | 43.2 | 852,461 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 43.05 per share. | 25 Jul 2022 | 3,600 | 19,734 | - | 43.1 | 154,985 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 43.19 per share. | 24 Jun 2022 | 23,333 | 23,334 | - | 43.2 | 1,007,694 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | Sale of securities on an exchange or to another person at price $ 39.85 per share. | 16 May 2022 | 23,333 | 46,667 | - | 39.9 | 929,836 | Class A Ordinary Shares |
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 11 May 2022 | 70,000 | 70,000 | - | 0 | Class A Ordinary Shares | ||
| Royalty Pharma PLC (Class A) | Marshall Urist | EVP, Research & Investments | 11 May 2022 | 7,000 | 205,594 | - | - | LP interests in RPI US Partners 2019, LP |